Results 101 to 110 of about 303,632 (262)
Haematologica, 2019 Hydroxyurea is the standard treatment in high-risk patients with polycythemia vera. However, estimates of its effect in terms of clinical outcomes (thrombosis, bleeding, hematologic transformations and mortality) are lacking. We performed a meta-analysis
A. Ferrari +7 more
semanticscholar +1 more source
Catheterization and Cardiovascular Interventions, Volume 107, Issue 4, Page 934-943, March 1, 2026.ABSTRACT Background High‐altitude populations typically exhibit elevated hemoglobin (Hb) levels due to chronic hypoxic exposure; however, the impact of this elevation on the risk of ST‐segment elevation myocardial infarction (STEMI) remains unclear. Existing evidence is primarily derived from low‐altitude populations and cannot be directly extrapolated
Jing Li +10 more
wiley +1 more source
Characteristics and clinical significance of cytogenetic abnormalities in polycythemia vera
Haematologica, 2017 Up to 20% of patients with polycythemia vera have karyotypic abnormalities at the time of the initial diagnosis. However, the cytogenetic abnormalities in polycythemia vera have not been well characterized and their prognostic impact is largely unknown ...
Guilin Tang +13 more
doaj +1 more source
Two-hit model of leukemogenesis in the evolution of polycythemia vera to acute myeloid leukemia [PDF]
, 2009 Polycythemia vera (PV) is a chronic myeloproliferative disorder that can evolve to marrow fibrosis or acute leukemia (AML). Cytogenetic alterations can be detected in around 25% of patients at diagnosis and in up to 50% of those with progression.
Chauffaille, Maria de Lourdes Lopes Ferrari +2 more
core +1 more source
How I Treat Polycythemia Vera.
Blood, 2019 Since its discovery 125 years ago, polycythemia vera (PV) has been a challenge to the clinicians responsible for its diagnosis and management, and the scientists attempting to define its molecular basis.
J. Spivak
semanticscholar +1 more source
Clinical Pharmacology in Drug Development, Volume 15, Issue 3, March 2026.Abstract Givinostat is a class I/II histone deacetylase inhibitor indicated for Duchenne muscular dystrophy (DMD). The study evaluated the effect of therapeutic and supratherapeutic givinostat doses on the QT/QTc interval. Healthy volunteers received each treatment—givinostat hydrochloride monohydrate oral suspension as a therapeutic (100 mg) or ...
Eugenio Mercuri +7 more
wiley +1 more source
Polycythemia Vera: New Diagnostic Concept and Its Types
Клиническая онкогематология, 2016 Polycythemia vera (PV) is a clonal Ph-negative myeloproliferative disorder characterized by excessive myeloid proliferation of three hematopoietic cell lineages leading to ineffective myelopoiesis.
Alla Mikhailovna Kovrigina, V. V. Baikov
doaj +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 629-640, March 2026.Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich +5 more
wiley +1 more source
JAAD Case Reports, 2019 Sarcoidosis is a chronic multisystem inflammatory disorder characterized by the formation of immune granulomas that may lead to serious, often irreversible, disability and significant disease-associated mortality.1 Current understanding suggests that ...
Jenny J. Wei +4 more
semanticscholar +1 more source
What's Your Diagnosis? A Case of Extreme Thrombocytosis in a Dog
Veterinary Clinical Pathology, EarlyView.
Stephanie F. Anderson +5 more
wiley +1 more source